Company Overview - Praxis Precision Medicines is a Boston-based biotechnology company focused on developing novel therapies for neurological and psychiatric disorders characterized by neuronal imbalance [6] - The company has a pipeline targeting major depressive disorder, essential tremor, and rare epilepsies, emphasizing precision medicine and targeted treatments [6] - As of February 17, 2026, the company's stock price was $328.04, reflecting a significant increase of 320% over the prior year [8] Financial Performance - The company reported a trailing twelve months (TTM) revenue of $7.46 million and a net income loss of $273.04 million [4] - Praxis ended 2025 with $926 million in cash and investments, supplemented by an additional $621 million in financing in January 2026, extending its financial runway into 2028 [10][11] - Research and development spending for 2025 reached $267 million, indicating a late-stage push across multiple programs [11] Recent Developments - On February 17, 2026, Perceptive Advisors LLC disclosed a purchase of 431,432 shares of Praxis Precision Medicines, valued at approximately $80.34 million, increasing its stake significantly [2] - The quarter-end value of Perceptive Advisors' position in Praxis increased by $505.38 million due to the share purchase and subsequent stock price movement [2] - Praxis has submitted two New Drug Applications (NDAs) to the FDA for ulixacaltamide in essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) [10] Market Position and Strategy - The company operates a biopharmaceutical business model focused on research, clinical development, and commercialization of proprietary drug candidates [9] - Praxis targets healthcare providers and specialists in neurology and psychiatry, aiming to address unmet medical needs in these fields [9] - The recent increase in portfolio weightings for Praxis reflects a transition from a pipeline story to a pending commercial launch, indicating potential for rapid changes in investor sentiment [7]

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underper ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underper ...

Praxis Precision Medicines (NasdaqGS:PRAX) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsDan Ferry - VP of Investor RelationsMarcio Souza - President and CEOTim Kelly - CFOConference Call ParticipantsAmi Fadia - AnalystAndrew Tsai - AnalystAthena Chin - AnalystBenjamin Burnett - AnalystBrian Skorney - AnalystDavid Hoang - Equity AnalystDouglas Tsao - AnalystFrancois Brisebois - AnalystJay Olson - AnalystJoon Lee - AnalystJustin Walsh - AnalystKambiz Yazdi - AnalystYasmeen Rahimi - ...

Praxis Precision Medicines (NasdaqGS:PRAX) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsDan Ferry - VP of Investor RelationsMarcio Souza - President and CEOTim Kelly - CFOConference Call ParticipantsAmi Fadia - AnalystAndrew Tsai - AnalystAthena Chin - AnalystBenjamin Burnett - AnalystBrian Skorney - AnalystDavid Hoang - Equity AnalystDouglas Tsao - AnalystFrancois Brisebois - AnalystJay Olson - AnalystJoon Lee - AnalystJustin Walsh - AnalystKambiz Yazdi - AnalystYasmin Rahimi - S ...

Praxis Precision Medicines (NasdaqGS:PRAX) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker12Good day, and thank you for standing by. Welcome to the Praxis Precision Medicines fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. You will then hear an automated message advising y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________ Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (St ...

Financial Performance - The company reported a net loss of $303.3 million for the year ended December 31, 2025, compared to a net loss of $182.8 million in 2024[14]. - Net loss for the year ended December 2025 was $303,268,000, which is a 66% increase from the net loss of $182,819,000 in 2024[31]. - Net loss per share attributable to common stockholders was $13.48 for 2025, compared to $10.21 for 2024, indicating a 32% increase in loss per share[31]. - Collaboration revenue was $0 for the year ended December 2025, down from $8,553,000 in 2024, indicating a decline in collaboration activities[31]. - Total operating expenses for the year ended December 2025 were $326,198,000, a significant increase of 56% from $208,718,000 in 2024[31]. Cash and Investments - As of December 31, 2025, Praxis had $926.1 million in cash and investments, an increase of $456.6 million from $469.5 million in 2024, primarily due to net proceeds from a public offering[9][11]. - Cash and cash equivalents increased to $357,329,000 in December 2025 from $215,372,000 in December 2024, a growth of 66%[29]. - Marketable securities rose to $568,759,000 in December 2025, up from $254,156,000 in December 2024, representing a 124% increase[29]. - Total assets increased to $937,907,000 in December 2025 from $483,110,000 in December 2024, representing a growth of 94%[29]. Research and Development - Research and development expenses for the fourth quarter of 2025 were $77.5 million, up from $56.3 million in the same quarter of 2024, with a total of $267.1 million for the year[12]. - Research and development expenses rose to $267,115,000 for the year ended December 2025, up 75% from $152,413,000 in 2024[31]. - Praxis plans to nominate a development candidate for each of its three early-stage antisense oligonucleotide therapeutic initiatives in the first half of 2026[10]. Drug Development and Commercialization - Praxis submitted two new drug applications (NDA) for ulixacaltamide and relutrigine to the FDA, with pre-launch activities expected to accelerate through 2026[1][3]. - Ulixacaltamide is the first investigational therapy to show positive results in a Phase 3 program for essential tremor, with over 200,000 patients expressing interest in the Essential3 program[4][6]. - The revenue potential of the four assets in development, including ulixacaltamide and relutrigine, is estimated to exceed $20 billion[3]. - Enrollment in the EMERALD study for broad developmental and epileptic encephalopathies (DEEs) is expected to be completed in the second half of 2026[10]. - Praxis is preparing for the commercial launch of relutrigine, including hiring key commercial roles and building inventory[10]. - The POWER1 Phase 3 study for focal onset seizures completed enrollment and exceeded its original target, with topline results expected in Q2 2026[10].

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December 31, 2025 and ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...